Table 4 Clinical trials based on MSCs-based therapies in liver diseases (e.g., ALF)
Condition | Cell Source | Participant no | Main results (ref) |
|---|---|---|---|
Primary biliary cirrhosis | Allogeneic UC | 7 | Robust attenuation in serum ALP and GGT levels [168] |
Liver failure | Allogeneic UC | 43 | Enchantment in the survival rates without side effects [162] |
HBV-induced liver cirrhosis | Autologous BM | 56 | Improving the Treg/Th17 cell ration [171] |
Liver cirrhosis | Autologous BM | 25 | Removing the HCV RNA caused by transplanted MSCs-mediated paracrine effect [211] |
Decompensated liver cirrhosis | Autologous BM | 4 | Improved the quality of life without serious side effects [167] |
Alcoholic liver cirrhosis | Autologous BM | 12 | No side effects in concomitant with histological and quantitative amelioration [212] |
HCV-induced liver cirrhosis | Autologous BM | 40 | Normalization of liver enzymes levels in association with restoration in liver function [213] |
Liver cirrhosis | Autologous BM | 8 | Improved liver function evidenced by enhanced serum albumin and reduced total bilirubin[172] |
Liver failure | Autologous BM-derived hepatocyte | 40 | Improvement in ascites, lower limb edema as well as serum albumin levels [163] |
Decompensated liver cirrhosis | Allogeneic UC | 45 | Improved level function documented with enhanced serum albumin levels and reduced total bilirubin levels [180] |
HCV-induced liver cirrhosis | Autologous BM | 20 | Amelioration of liver function in Egyptian patients [170] |
HCV-induced liver cirrhosis | Autologous BM | 25 | Partial rescue in liver function [169] |
Decompensated liver cirrhosis | Autologous BM | 27 | No significant beneficial effect [174] |
Liver failure | Allogeneic BM | 110 | Improved overall survival and also reduced incidence of severe infections [164] |
Liver cirrhosis | Allogeneic (UC, UCB, BM) | 26 | Stromal cell injection by peripheral vein was safe and partially effective [173] |
HBV-induced liver cirrhosis | Allogeneic UC | 40 | Enhanced IL-10 levels and also reduced IL-6 and TNF-É‘ levels [214] |
Ischemic-type biliary lesions following liver transplantation | Allogeneic UC | 12 | Stem cell injection was safe and elicited favorable short-term outcomes [215] |
Alcoholic liver cirrhosis | Autologous BM | 72 | Ameliorated histologic fibrosis and liver normal activity [216] |
Liver allograft rejection | Allogeneic UC | 27 | Improved Treg/Th17 cell ratio [217] |
Liver allograft rejection | Allogeneic BM | 10 | No side effect [218] |